🟢 Biovie is trading 6.5% up today amid anticipation of ADDRESS-LC topline results

Biovie is trading 6.5% up at $2.13, possibly supported by anticipation of ADDRESS-LC topline results targeted before September 30, 2026.

• Shares rose from the September 4, 2026 close of $2.00.
• No company-specific announcement was identified on September 8, 2026.
• The August 31, 2026 update confirmed completion of the ADDRESS-LC treatment phase and the results target, but Biovie did not explicitly link the move to that update.